Back to results
US 8,524,230 B2Granted
Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
AssigneeMerck Sharp & Dohme Corp.
InventorsDaniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver
Life of this patent
Estimating the term…
Abstract
Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
Claims1
A method of treating an autoimmune-mediated ocular inflammatory disease (AOID) comprising administering to a subject in need of such treatment an antagonist of interleukin-23 (IL-23), wherein the AOID is chronic uveitis and the antagonist is a monoclonal antibody that specifically binds to the p19 subunit of IL-23.
Dependencies are inferred from the claim text.